Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus

Expert Opinion on Biological Therapy

Volumn 7, Issue 7, 2007, Pages 951-963

  Trucco, Massimo ^a,b   Giannoukakis, Nick ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Dendritic cells; Diabetes; Immunotherapy; Tolerance

Indexed keywords

AUTOIMMUNITY; DENDRITIC CELL; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANIMALS; AUTOIMMUNITY; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES, REGULATORY;

EID: 34547621453     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.7.951     Document Type: Review

References (213)

1. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
2. LUTZ MB, SCHULER G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 23(9):445-449.
3. STEINMAN RM, HAWIGER D, NUSSENZWEIG MC: Tolerogenic dendritic cells. Ann. Rev. Immunol. (2003) 21:685-711.
4. STEINMAN RM, TURLEY S, MELLMAN I, INABA K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. (2000) 191(3):411-416.
5. VLAD G, CORTESINI R, SUCIU-FOCA N: License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol. (2005) 174(10):5907-5914.
6. SMITS HH, DE JONG EC, WIERENGA EA, KAPSENBERG ML: Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol. (2005) 26(3):123-129.
7. SMITS HH, ENGERING A, VAN DER KLEIJ D et al.: Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin. Immunol. (2005) 115(6):1260-1267.
8. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. (2003) 198(2):235-247. •• Direct demonstration that DCs can expand Treg in vitro.
9. INABA K, METLAY JP, CROWLEY MT, STEINMAN RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. (1990) 172(2):631-640.
10. KUBACH J, BECKER C, SCHMITT E et al.: Dendritic cells: sentinels of immunity and tolerance. Int. J. Hematol. (2005) 81(3):197-203.
11. STEINMAN RM: Some interfaces of dendritic cell biology. APMIS (2003) 111(7-8):675-697.
12. STEINMAN RM, BONIFAZ L, FUJII S et al.: The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol. (2005) 560:83-97.
13. STEINMAN RM, NUSSENZWEIG MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl Acad. Sci. USA (2002) 99(1):351-358.
14. LIU YJ: Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell (2001) 106(3):259-262.
15. LIU YJ, KANZLER H, SOUMELIS V, GILLIET M: Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol (2001) 2(7):585-589.
16. BLUESTONE JA: Costimulation and its role in organ transplantation. Clin. Transplant. (1996) 10(1 Part 2):104-109.
17. CLARKSON MR, SAYEGH MH: T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation (2005) 80(5):555-563.
18. KISHIMOTO K, DONG VM, SAYEGH MH: The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr. Opin. Urol. (2000) 10(2):57-62.
19. LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Ann. Rev. Immunol. (1996) 14:233-258.
20. ROTHSTEIN DM, SAYEGH MH: T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev. (2003) 196:85-108.
21. SAYEGH MH, TURKA LA: T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. (1995) 6(4):1143-1150.
22. MANZ MG, TRAVER D, AKASHI K et al.: Dendritic cell development from common myeloid progenitors. Ann. NY Acad. Sci. (2001) 938:167-173; discussion 173-164.
23. MANZ MG, TRAVER D, MIYAMOTO T, WEISSMAN IL, AKASHI K: Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood (2001) 97(11):3333-3341.
24. MANFREDI AA, SABBADINI MG, ROVERE-QUERINI P: Dendritic cells and the shadow line between autoimmunity and disease. Arthritis Rheum. (2005) 52(1):11-15.
25. SUCIU-FOCA N, MANAVALAN JS, SCOTTO L et al.: Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int. Immunopharmacol. (2005) 5(1):7-11.
26. KOMULAINEN J, KNIP M, LOUNAMAA R et al.: Poor β-cell function after the clinical manifestation of Type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group. Diabet. Med. (1997) 14(7):532-537.
27. LAMPETER EF, KLINGHAMMER A, SCHERBAUM WA et al.: The Deutsche Nicotinamide Intervention Study: an attempt to prevent Type 1 diabetes. DENIS Group. Diabetes (1998) 47(6):980-984.
28. LARSEN MO, ROLIN B, GOTFREDSEN CF, CARR RD, HOLST JJ: Reduction of β cell mass: partial insulin secretory compensation from the residual β cell population in the nicotinamide-streptozotocin Gottingen minipig after oral glucose in vivo and in the perfused pancreas. Diabetologia (2004) 47(11):1873-1878.
29. LOHMANN T, KELLNER K, VERLOHREN HJ et al.: Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia (2001) 44(8):1005-1010.
30. MAYER A, RHARBAOUI F, THIVOLET C, ORGIAZZI J, MADEC AM: The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in Type 1 (insulin-dependent) diabetes mellitus. J. Clin. Endocrinol. Metab. (1999) 84(7):2419-2424.
31. PAPOZ L, LENEGRE F, HORS J et al.: Probability of remission in individual in early adult insulin dependent diabetic patients. Results from the Cyclosporine Diabetes French Study Group. Diabete. Metab. (1990) 16(4):303-310.
32. PETRONE A, GALGANI A, SPOLETINI M et al.: Residual insulin secretion at diagnosis of Type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab. Res. Rev. (2005) 21(3):271-275.
33. RASMUSSEN SB, SORENSEN TS, HANSEN JB et al.: Functional rest through intensive treatment with insulin and potassium channel openers preserves residual β-cell function and mass in acutely diabetic BB rats. Horm. Metab. Res. (2000) 32(7):294-300.
34. + diabetes with residual β-cell function. A case report. Diabetes Care (1999) 22(4):615-617.
35. SREENAN S, PICK AJ, LEVISETTI M et al.: Increased P-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes (1999) 48(5):989-996. •• Demonstration that clinical disease need not be associated with complete eradication of functional β-cell mass but that immunoregulation of insulitis can restore residual β-cell mass to a functional state and, therefore, 'reverse' the disease.
36. WEETS I, TRUYEN I, VERSCHRAEGEN I et al.: Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated Type 1 diabetes. Diabetologia (2006) 49(6):1158-1162.
37. ARNUSH M, SCARIM AL, HEITMEIER MR, KELLY CB, CORBETT JA: Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J. Immunol. (1998) 160(6):2684-2691.
38. CORBETT JA, MCDANIEL ML: Reversibility of interleukin-1 β-induced islet destruction and dysfunction by the inhibition of nitric oxide synthase. Biochem. J. (1994) 229(Part 3):719-724.
39. CORBETT JA, WANG JL, HUGHES JH et al.: Nitric oxide and cyclic GMP formation induced by interleukin 1β in islets of Langerhans. Evidence for an effector role of nitric oxide in islet dysfunction. Biochem. J. (1992) 287(Part 1):229-235.
40. CORBETT JA, WANG JL, MISKO TP et al.: Nitric oxide mediates IL-1 β-induced islet dysfunction and destruction: prevention by dexamethasone. Autoimmunity (1993) 15(2):145-153.
41. MA Z, RAMANADHAM S, CORBETT JA et al.: Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. J. Biol. Chem. (1996) 271(2):1029-1042.
42. MCDANIEL ML, KWON G, HILL JR, MARSHALL CA, CORBETT JA: Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. (1996) 211(1):24-32.
43. SCARIM AL, HEITMEIER MR, CORBETT JA: Irreversible inhibition of metabolic function and islet destruction after a 36-hour exposure to interleukin-1β. Endocrinology (1997) 138(12):5301-5307.
44. TRUDEAU JD, DUTZ JP, ARANY E et al.: Neonatal β-cell apoptosis: a trigger for autoimmune diabetes? Diabetes (2000) 49(1):1-7.
45. OLDSTONE MB: Molecular mimicry and autoimmune disease. Cell (1987) 50(6):819-820.
46. OLDSTONE MB: Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease. J. Autoimmun. (1989) 2(Suppl.):187-194.
47. OLDSTONE MB: Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. Curr. Top Microbiol. Immunol. (1989) 145:127-135.
48. CONRAD B, WEIDMANN E, TRUCCO G et al.: Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 371(6495):351-355.
49. CONRAD B, TRUCCO M: Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. (1994) 10(4):309-338.
50. JANSEN A, HOMO-DELARCHE F, HOOIJKAAS H et al.: Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β-cell destruction in NOD mice. Diabetes (1994) 43(5):667-675.
51. + macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on β-cell rest? J. Autoimmun. (1996) 9(3):341-348.
52. LO D, REILLY CR, SCOTT B et al.: Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur. J. Immunol. (1993) 23(7):1693-1698.
53. CLARE-SALZLER M, MULLEN Y: Marked dendritic cell-T cell cluster formation in the pancreatic lymph node of the non-obese diabetic mouse. Immunology (1992) 76(3):478-484.
54. HOGLUND P, MINTERN J, WALTZINGER C et al.: Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. (1999) 189(2):331-339.
55. SHIMIZU J, CARRASCO-MARIN E, KANAGAWA O, UNANUE ER: Relationship between β cell injury and antigen presentation in NOD mice. J. Immunol. (1995) 155(8):4095-4099.
56. GREEN EA, EYNON EE, FLAVELL RA: Local expression of TNF-α in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity (1998) 9(5):733-743.
57. DAHLEN E, DAWE K, OHLSSON L, HEDLUND G: Dendritic cells and macrophages are the first and major producers of TNF-α in pancreatic islets in the nonobese diabetic mouse. J. Immunol. (1998) 160(7):3585-3593.
58. + T cells to cause immunopathology. J. Exp. Med. (1998) 187(5):763- 774.
59. LUDEWIG B, EHL S, KARRERU U et al.: Dendritic cells efficiently induce protective antiviral immunity. J. Virol. (1998) 72(5):3812-3818.
60. LUDEWIG B, ODERMATT B, LANDMANN S, HENGARTNER H, ZINKERNAGEL RM: Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J. Exp. Med. (1998) 188(8):1493-1501.
61. CHRISTEN U, VON HERRATH MG: Transgenic animal models for Type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model. Transgenic Res. (2002) 11(6):587-595.
62. CHRISTEN U, VON HERRATH MG: Manipulating the Type 1 versus Type 2 balance in Type 1 diabetes. Immunol Res. (2004) 30(3):309-325.
63. CHRISTEN U, VON HERRATH MG: Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol. (2004) 40(14-15):1113-1120.
64. VON HERRATH MG: Regulation of virally induced autoimmunity and immunopathology: contribution of LCMV transgenic models to understanding autoimmune insulin-dependent diabetes mellitus. Curr. Top Microbiol. Immunol. (2002) 263:145-175.
65. GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13(1):114-119.
66. MATZINGER P: Tolerance, danger, and the extended family. Ann. Rev. Immunol. (1994) 12:991-1045.
67. MATZINGER P: An innate sense of danger. Semin. Immunol. (1998) 10(5):399-415.
68. MATZINGER P: Essay 1: the danger model in its historical context. Scand. J. Immunol. (2001) 54(1-2):4-9.
69. MATZINGER P: An innate sense of danger. Ann. NY Acad. Sci. (2002) 961:341-342.
70. MARLEAU AM, SINGH B: Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J. Autoimmun. (2002) 19(1-2):23-35.
71. SEN P, BHATTACHARYYA S, WALLET M et al.: NF-κB hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J. Immunol. (2003) 170(4):1770-1780.
72. WEAVER DJ Jr, POLIGONE B, BUI T et al.: Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive I κB kinase. J. Immunol. (2001) 167(3):1461- 1468.
73. WHEAT W, KUPFER R, GUTCHES DG et al.: Increased NF-κB activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur. J. Immunol. (2004) 34(5):1395-1404.
74. BOUDALY S, MORIN J, BERTHIER R, MARCHE P, BOITARD C: Altered dendritic cells (DC) might be responsible for regulatory T cell imbalance and autoimmunity in nonobese diabetic (NOD) mice. Eur. Cytokine Netw. (2002) 13(1):29-37.
75. NIKOLIC T, BUNK M, DREXHAGE HA, LEENEN PJ: Bone marrow precursors of nonobese diabetic mice develop into defective macrophage-like dendritic cells in vitro. J. Immunol. (2004) 173(7):4342-4351.
76. STRID J, LOPES L, MARCINKIEWICZ J et al.: A defect in bone marrow derived dendritic cell maturation in the nonobesediabetic mouse. Clin. Exp. Immunol. (2001) 123(3):375-381.
77. EIBL N, SPATZ M, FISCHER GF et al.: Impaired primary immune response in Type-1 diabetes: results from a controlled vaccination study. Clin. Immunol. (2002) 103(3 Part 1):249-259.
78. MCMAHON MM, BISTRIAN BR: Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect. Dis. Clin. North Am. (1995) 9(1):1-9.
79. WHEAT LJ: Infection and diabetes mellitus. Diabetes Care (1980) 3(1):187-197.
80. PENG R, LI Y, BREZNER K, LITHERLAND S, CLARE-SALZLER MJ: Abnormal peripheral blood dendritic cell populations in Type 1 diabetes. Ann. NY Acad. Sci. (2003) 1005:222-225.
81. SUMMERS KL, BEHME MT, MAHON JL, SINGH B: Characterization of dendritic cells in humans with Type 1 diabetes. Ann. NY Acad. Sci. (2003) 1005:226-229.
82. SUMMERS KL, MARLEAU AM, MAHON JL et al.: Reduced IFN-α secretion by blood dendritic cells in human diabetes. Clin. Immunol. (2006) 121(1):81-89.
83. COATES PT, THOMSON AW: Dendritic cells, tolerance induction and transplant outcome. Am. J. Transplant. (2002) 2(4):299-307.
84. DAVIS ID, JEFFORD M, PARENTE P, CEBON J: Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. (2003) 73(1):3-29.
85. DI NICOLA M, ANICHINI A, MORTARINI R et al.: Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytokines Cell Mol. Ther. (1998) 4(4):265-273.
86. HACKSTEIN H, MORELLI AE, THOMSON AW: Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. (2001) 22(8):437-442.
87. HARDIN JA: Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann. Rheum. Dis. (2005) 64(Suppl. 4):iv86-iv90.
88. MORELLI AE, THOMSON AW: Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev. (2003) 196:125-146.
89. NOURI-SHIRAZI M, THOMSON AW: Dendritic cells as promoters of transplant tolerance. Expert Opin. Biol. Ther. (2006) 6(4):325-339.
90. PAUL S, CALMELS B, ACRES RB: Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr. Gene Ther. (2002) 2(1):91-100.
91. FEILI-HARIRI M, DONG X, ALBER SM et al.: Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes (1999) 48(12):2300-2308.
92. STEINMAN RM, INABA K, TURLEY S, PIERRE P, MELLMAN I: Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum. Immunol. (1999) 60(7):562-567.
93. BOTTINO R, LEMARCHAND P, TRUCCO M, GIANNOUKAKIS N: Gene- and cell-based therapeutics for Type I diabetes mellitus. Gene Ther. (2003) 10(10):875-889.
94. CHEN D, SUNG R, BROMBERG JS: Gene therapy in transplantation. Transpl. Immunol. (2002) 9(2-4):301-314.
95. GIANNOUKAKIS N, RUDERT WA, ROBBINS PD, TRUCCO M: Targeting autoimmune diabetes with gene therapy. Diabetes (1999) 48(11):2107-2121.
96. GIANNOUKAKIS N, THOMSON A, ROBBINS P: Gene therapy in transplantation. Gene Ther. (1999) 6(9):1499-1511.
97. GIANNOUKAKIS N, TRUCCO M: Gene therapy for Type 1 diabetes. Am. J. Ther. (2005) 12(6):512-528.
98. TARNER IH, FATHMAN CG: The potential for gene therapy in the treatment of autoimmune disease. Clin. Immunol. (2002) 104(3):204-216.
99. TARNER IH, SLAVIN AJ, MCBRIDE J et al.: Treatment of autoimmune disease by adoptive cellular gene therapy. Ann. NY Acad. Sci. (2003) 998:512-519.
100. TRUCCO M, ROBBINS PD, THOMSON AW, GIANNOUKAKIS N: Gene therapy strategies to prevent autoimmune disorders. Curr. Gene Ther. (2002) 2(3):341-354.
101. + T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front. Biosci. (2006) 11:1360-1370.
102. HUGUES S, BOISSONNAS A, AMIGORENA S, FETLER L: The dynamics of dendritic cell-T cell interactions in priming and tolerance. Curr. Opin. Immunol. (2006) 18(4):491-495.
103. BEISSERT S, SCHWARZ A, SCHWARZ T: Regulatory T cells. J. Invest. Dermatol. (2006) 126(1):15-24.
104. ENK AH: DCs and cytokines cooperate for the induction of tregs. Ernst. Schering Res. Found Workshop (2006) 56:97-106.
105. + regulatory T cells. Front. Biosci. (2006) 11:1014-1023.
106. LOHR J, KNOECHEL B, ABBAS AK: Regulatory T cells in the periphery. Immunol. Rev. (2006) 212:149-162.
107. RONCAROLO MG, GREGORI S, BATTAGLIA M et al.: Interleukin-10- secreting Type 1 regulatory T cells in rodents and humans. Immunol. Rev. (2006) 212:28-50.
108. + Foxp3+ regulatory T cells. Immunol. Rev. (2006) 212:60-73.
109. TANG Q, BLUESTONE JA: Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. (2006) 212:217-237.
110. VERHAGEN J, BLASER K, AKDIS CA, AKDIS M: Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more. Immunol. Allergy Clin. North Am. (2006) 26(2):207-231, vi.
111. + regulatory T cells and immune tolerance. Autoimmunity (2006) 39(4):269-276.
112. ANDERSON CC, CHAN WF: Mechanisms and models of peripheral CD4 T cell self-tolerance. Front. Biosci. (2004) 9:2947-2963.
113. BALOMENOS D, MARTINEZ AC: Cell-cycle regulation in immunity, tolerance and autoimmunity. Immunol. Today (2000) 21(11):551-555.
114. BRENNAN PJ, SAOUAF SJ, GREENE MI, SHEN Y: Anergy and suppression as coexistent mechanisms for the maintenance of peripheral T cell tolerance. Immunol. Res. (2003) 27(2-3):295.
115. GOODNOW CC, SPRENT J, FAZEKAS DE ST GROTH B, VINUESA CG: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435(7042):590-597.
116. LECHLER R, CHAI JG, MARELLI-BERG F, LOMBARDI G: The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology (2001) 103(3):262-269.
117. LECHLER R, CHAI JG, MARELLI-BERG F, LOMBARDI G: T-cell anergy and peripheral T-cell tolerance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1409):625-637.
118. SAOUAF SJ, BRENNAN PJ, SHEN Y, GREENE MI: Mechanisms of peripheral immune tolerance: conversion of the immune to the unresponsive phenotype. Immunol. Res. (2003) 28(3):193-199.
119. SINGH NJ, SCHWARTZ RH: Primer: mechanisms of immunologic tolerance. Nat. Clin. Pract. Rheumatol. (2006) 2(1):44-52.
120. BATTAGLIA M, GREGORI S, BACCHETTA R, RONCAROLO MG: Tr1 cells: from discovery to their clinical application. Semin. Immunol. (2006) 18(2):120-127.
121. MENNECHET FJ, UZE G: IFN-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 107(11):4417-4423.
122. RUTELLA S, BONANNO G, PROCOLI A et al.: Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/ neg accessory cells with dendritic-cell features. Blood (2006) 108(1):218-227.
123. VIGOUROUX S, YVON E, BIAGI E, BRENNER MK: Antigen-induced regulatory T cells. Blood (2004) 104(1):26-33.
124. + regulatory T cells in human thymus. Nature (2005) 436(7054):1181-1185.
125. YVON ES, VIGOUROUX S, ROUSSEAU RF et al.: Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood (2003) 102(10):3815-3821.
126. DHODAPKAR MV, STEINMAN RM, KRASOVSKY J, MUNZ C, BHARDWAJ N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. (2001) 193(2):233-238.
127. JONULEIT H, SCHMITT E, SCHULER G, KNOP J, ENK AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. (2000) 192(9):1213-1222.
128. + T cells without reversing their suppressive function. J. Immunol. (2005) 175(11):7332-7340.
129. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. (2004) 199(11):1467-1477.
130. + T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes (2006) 55(1):158-170.
131. MA L, QIAN S, LIANG X et al.: Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes (2003) 52(8):1976-1985.
132. MACHEN J, HARNAHA J, LAKOMY R et al.: Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. (2004) 173(7):4331- 4341.
133. GORDON EJ, WICKER LS, PETERSON LB et al.: Autoimmune diabetes and resistance to xenograft transplantation tolerance in NOD mice. Diabetes (2005) 54(1):107-115.
134. MARKEES TG, SERREZE DV, PHILLIPS NE et al.: NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes (1999) 48(5):967-974.
135. PEARSON T, MARKEES TG, SERREZE DV et al.: Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J. Immunol. (2003) 171(1):185-195.
136. PEARSON T, MARKEES TG, SERREZE DV et al.: Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann. NY Acad. Sci. (2003) 1005:148-156.
137. PEARSON T, MARKEES TG, WICKER LS et al.: NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes (2003) 52(2):321- 326.
138. ROSSINI AA: Autoimmune diabetes and the circle of tolerance. Diabetes (2004) 53(2):267-275.
139. ROSSINI AA, MORDES JP, GREINER DL, STOFF JS: Islet cell transplantation tolerance. Transplantation (2001) 72(8 Suppl.):S43-S46.
140. SEUNG E, MORDES JP, GREINER DL, ROSSINI AA: Induction of tolerance for islet transplantation for Type 1 diabetes. Curr. Diab. Rep. (2003) 3(4):329-335.
141. KARNES RJ, WHELAN CM, KWON ED: Immunotherapy for prostate cancer. Curr. Pharm. Des. (2006) 12(7):807-817.
142. KIKUCHI T: Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. (2006) 208(1):1-8.
143. PINZON-CHARRY A, SCHMIDT C, LOPEZ JA: Dendritic cell immunotherapy for breast cancer. Expert Opin. Biol. Ther. (2006) 6(6):591-604.
144. RIKER AI, JOVE R, DAUD AI: Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front. Biosci. (2006) 11:1-14.
145. SAITO H, FRLETA D, DUBSKY P, PALUCKA AK: Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North Am. (2006) 20(3):689-710.
146. XIA D, MOYANA T, XIANG J: Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. (2006) 16(3):241-259.
147. BUTTERFIELD LH, RIBAS A, DISSETTE VB et al.: A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res. (2006) 12(9):2817-2825.
148. DILLMAN R, SELVAN S, SCHILTZ P et al.: Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother. Radiopharm. (2004) 19(5):658-665.
149. HERSEY P, MENZIES SW, HALLIDAY GM et al.: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. (2004) 53(2):125-134.
150. KYTE JA, MU L, AAMDAL S et al.: Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. (2006) 13(10):905-918.
151. LODGE PA, JONES LA, BADER RA, MURPHY GP, SALGALLER ML: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a Phase II clinical trial. Cancer Res. (2000) 60(4):829-833.
152. LOU E, MARSHALL J, AKLILU M et al.: A Phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin. Colorectal Cancer (2006) 5(5):368-371.
153. MARTEN A, FLIEGER D, RENOTH S et al.: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother. (2002) 51(11-12):637-644.
154. MORSE MA, NAIR SK, BOCZKOWSKI D et al.: The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer (2002) 32(1):1-6.
155. O'ROURKE MG, JOHNSON M, LANAGAN C et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. (2003) 52(6):387-395.
156. PECHER G, FLARING A, KAISER L, THIEL E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. (2002) 51(11-12):669.
157. SLINGLUFF CL Jr, PETRONI GR, YAMSHCHIKOV GV et al.: Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in ranulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. (2003) 21(21):4016-4026.
158. TJOA BA, SIMMONS SJ, BOWES VA et al.: Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36(1):39-44.
159. TJOA BA, SIMMONS SJ, ELGAMAL A et al.: Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate (1999) 40(2):125-129.
160. WEIHRAUCH MR, ANSEN S, JURKIEWICZ E et al.: Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. (2005) 11(16):5993-6001.
161. YAMANAKAR, ABE T, YAJIMA N et al.: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer (2003) 89(7):1172-1179.
162. YAMANAKA R, HOMMA J, YAJIMA N et al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. (2005) 11(11):4160- 4167.
163. O'DOHERTY U, PENG M, GEZELTER S et al.: Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology (1994) 82(3):487-493.
164. GROUARD G, RISSOAN MC, FILGUEIRA L et al.: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. (1997) 185(6):1101-1111.
165. CLARE-SALZLER MJ, BROOKS J, CHAI A, VAN HERLE K, ANDERSON C: Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest. (1992) 90(3):741-748. •• The first observation that DC administration can prevent diabetes. Of interest is that pancreatic lymph node DCs were therapeutic, which, although at the time not completely understood mechanistically, today is consistent with the mechanisms of immunoregulation taking place inside lymph nodes anatomically proximal to the affected tissues in autoimmune disease.
166. FEILI-HARIRI M, FALKNER DH, GAMBOTTO A et al.: Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum. Gene Ther. (2003) 14(1):13-23.
167. ADORINI L: Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci. (2003) 987:258-261.
168. KARED H, MASSON A, ADLE-BIASSETTE H et al.: Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. Diabetes (2005) 54(1):78-84.
169. MORIN J, FAIDEAU B, GAGNERAULT MC et al.: Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Clin. Exp. Immunol. (2003) 134(3):388-395.
170. PAPACCIO G, NICOLETTI F, PISANTI FA, BENDTZEN K, GALDIERI M: Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology (2000) 141(4):1500-1505.
171. + myeloid progenitor cells that differentiate in vivo into resting dendritic cells. Diabetes (2005) 54(2):434-442.
172. MENGES M, ROSSNER S, VOIGTLANDER C et al.: Repetitive injections of dendritic cells matured with TNF-α induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. (2002) 195(1):15-21.
173. + T cells. J. Immunol. (2005) 174(11):7433-7439.
174. + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. (2005) 174(11):7006-7013.
175. CHORNY A, GONZALEZ-REY E, FERNANDEZ-MARTIN A, GANEA D, DELGADO M: Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood (2006) 107(9):3787-3794.
176. CHORNY A, GONZALEZ-REY E, FERNANDEZ-MARTIN A et al.: Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl. Acad. Sci. USA (2005) 102(38):13562-13567.
177. + T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol. (2004) 172(4):1991-1995.
178. KIM SH, KIMS, EVANS CH et al.: Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. (2001) 166(5):3499-3505.
179. KIM SH, LECHMAN ER, BIANCO N et al.: Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. (2005) 174(10):6440-6448.
180. WHALEN JD, THOMSON AW, LU L, ROBBINS PD, EVANS CH: Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: evidence for involvement of genetically modified dendritic cells and macrophages. Mol. Ther. (2001) 4(6):543-550.
181. HOVES S, KRAUSE SW, HALBRITTER D et al.: Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J. Immunol. (2003) 170(11):5406-5413.
182. + T cells by Fas ligand (Fas L/CD95L)-expressing killer-dendritic cells. Immunobiology (2004) 208(5):463-475.
183. -) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 62(5):659-665.
184. LUTZ MB, SURI RM, NIIMI M et al.: Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur. J. Immunol. (2000) 30(7):1813-1822.
185. RASTELLINI C, LU L, RICORDI C et al.: Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 60(11):1366-1370.
186. SATO K, YAMASHITA N, YAMASHITA N, BABA M, MATSUYAMA T: Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity (2003) 18(3):367-379.
187. GREGORI S, CASORATI M, AMUCHASTEGUI S et al.: Regulatory T cells induced by 1α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. (2001) 167(4):1945-1953.
188. GRIFFIN MD, LUTZ W, PHAN VA et al.: Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(12):6800-6805.
189. HACKSTEIN H, MORELLI AE, LARREGINA AT et al.: Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. (2001) 166(12):7053- 7062.
190. HACKSTEIN H, TANER T, ZAHORCHAK AF et al.: Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 101(11):4457-4463.
191. HACKSTEIN H, THOMSON AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. (2004) 4(1):24-34.
192. LEE JI, GANSTER RW, GELLER DA et al.: Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced NF-κB. Transplantation (1999) 68(9):1255-1263.
193. MA L, RUDERT WA, HARNAHA J et al.: Immunosuppressive effects of glucosamine. J. Biol. Chem. (2002) 277(42):39343-39349.
194. MATASIC R, DIETZ AB, VUK-PAVLOVIC S: Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology (2000) 101(1):53-60.
195. MATYSZAK MK, CITTERIO S, RESCIGNO M, RICCIARDI-CASTAGNOLI P: Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol. (2000) 30(4):1233-1242.
196. MEHLING A, GRABBE S, VOSKORT M et al.: Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J. Immunol. (2000) 165(5):2374-2381.
197. NOURI-SHIRAZI M, GUINET E: Direct and indirect cross-tolerance of alloreactive T cells by dendritic cells retained in the immature stage. Transplantation (2002) 74(7):1035-1044.
198. PENNA G, ADORINI L: 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. (2000) 164(5):2405-2411.
199. PIEMONTI L, MONTI P, ALLAVENA P et al.: Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. (1999) 162(11):6473-6481.
200. ROELEN DL, SCHUURHUIS DH, VAN DEN BOOGAARDT DE et al.: Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells. Transplantation (2003) 76(11):1608-1615.
201. THOMAS JM, CONTRERAS JL, JIANG XL et al.: Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation (1999) 68(11):1660-1673.
202. VOSTERS O, NEVE J, DE WIT D et al.: Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory T cells. Transplantation (2003) 75(3):383-389.
203. BONHAM CA, PENG L, LIANG X et al.: Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-κB oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J. Immunol. (2002) 169(6):3382-3391.
204. COATES PT, KRISHNAN R, KIRETA S, JOHNSTON J, RUSS GR: Human myeloid dendritic cells transduced with an adenoviral IL-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther. (2001) 8(16):1224-1233.
205. GORCZYNSKI RM, BRANSOM J, CATTRAL M et al.: Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGF-β and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin. Immunol. (2000) 95(3):182-189.
206. LU L, GAMBOTTO A, LEE WC et al.: Adenoviral delivery of CTLA4-Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther. (1999) 6(4):554-563.
207. MIN WP, GORCZYNSKI R, HUANG XY et al.: Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. (2000) 164(1):161-167.
208. O'ROURKE RW, KANG SM, LOWER JA et al.: A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival. Transplantation (2000) 69(7):1440-1446.
209. TAKAYAMA T, MORELLI AE, ROBBINS PD, TAHARA H, THOMSON AW: Feasibility of CTLA4-Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther. (2000) 7(15):1265-1273.
210. TAKAYAMA T, NISHIOKA Y, LU L et al.: Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 66(12):1567-1574.
211. TERNESS P, BAUER TM, ROSE L et al.: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. (2002) 196(4):447-457.
212. GARROVILLO M, ALI A, OLUWOLE SF: Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells. Transplantation (1999) 68(12):1827-1834.
213. TANER T, HACKSTEIN H, WANG Z, MORELLI AE, THOMSON AW: Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. (2005) 5(2):228-236.